Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)DivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Change in Cash (2019 - 2025)

Historic Change in Cash for BridgeBio Pharma (BBIO) over the last 7 years, with Q3 2025 value amounting to -$106.0 million.

  • BridgeBio Pharma's Change in Cash rose 2515.59% to -$106.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $237.2 million, marking a year-over-year increase of 30403.56%. This contributed to the annual value of $288.5 million for FY2024, which is 140241.96% up from last year.
  • BridgeBio Pharma's Change in Cash amounted to -$106.0 million in Q3 2025, which was up 2515.59% from $208.4 million recorded in Q2 2025.
  • In the past 5 years, BridgeBio Pharma's Change in Cash registered a high of $275.4 million during Q4 2024, and its lowest value of -$198.0 million during Q3 2021.
  • Over the past 5 years, BridgeBio Pharma's median Change in Cash value was $13.1 million (recorded in 2022), while the average stood at $15.1 million.
  • Per our database at Business Quant, BridgeBio Pharma's Change in Cash surged by 254818.64% in 2021 and then crashed by 26976.22% in 2025.
  • Over the past 5 years, BridgeBio Pharma's Change in Cash (Quarter) stood at $213.3 million in 2021, then crashed by 132.3% to -$68.9 million in 2022, then plummeted by 87.82% to -$129.4 million in 2023, then surged by 312.79% to $275.4 million in 2024, then crashed by 138.5% to -$106.0 million in 2025.
  • Its Change in Cash was -$106.0 million in Q3 2025, compared to $208.4 million in Q2 2025 and -$140.5 million in Q1 2025.